GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2021-2028

Lifesciences | Healthcare & Wellness

GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2021-2028

Market by Therapeutics and Diagnostics and Regional Outlook | Forecast 2021-2028

Request Free Sample

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

The detailed analysis of the Alzheimer’s disease therapeutics and diagnostics market shows that, in terms of revenue, the industry is estimated to grow at a CAGR of 5.56% during the forecasting years 2021-2028. It was valued at $6585.9 million in 2020, and is expected to amount to $10149.5 million by 2028.


Report scope can be customized per your requirements. Request For Customization

Alzheimer’s is a degenerative, progressive ailment that attacks the brain’s neurons, resulting in memory loss, language skills, thinking, and behavioral changes.

The increasing investments in biomarkers for drug development and the early detection of Alzheimer’s disease can lead to higher adoption rates of biomarker-based diagnostics as well as the development of new therapeutics, which, in turn, have fueled the Alzheimer’s Disease Therapeutics and Diagnostics market growth worldwide.

During the outbreak of COVID-19, some clinical trials related to Alzheimer’s disease were being postponed due to the fear of contamination. A proportion of people with dementia are in care homes. They tend to be older and have multiple other health conditions. Currently, a number of drugs are in the late pipeline stages of drug development for AD. In fact, there are more candidates than ever, and there are many novel drug applicants aimed at addressing the actual pathological cause of AD, which the currently marketed drugs are unable to address.

The study aims to get an overview of the Alzheimer’s disease therapeutics and diagnostics market in terms of various factors. Within this report, the key insight and the market summary regarding the Alzheimer’s disease therapeutics and diagnostics industry have been discussed. Also, the impact of COVID-19 on the Alzheimer’s disease therapeutics and diagnostics market, key buying impact analysis, industry components, different phases of Alzheimer’s disease, market attractiveness index, vendor scorecard, and key strategic developments have been studied in detail.

Factors like the growing prevalence of dementia in the aged population, the growing cases of Alzheimer’s disease in developed countries, the launch of new drugs, and the prevailing clinical trials are driving the market growth. However, the industry is facing restraints, such as stringent regulations associated with drug development & clinical trials and failure of the late-stage drugs to induce significant improvement in symptoms, which are obstructing the Alzheimer’s disease therapeutics and diagnostics industry’s growth.

Key opportunities like the emerging novel diagnostic technologies for the treatment of Alzheimer’s disease can be leveraged by the industry to reach the projected growth.


Geographies covered in the Alzheimer’s disease therapeutics and diagnostics market by region are:

•           North America: The United States and Canada

•           Europe: Russia, Spain, the United Kingdom, Germany, France, Italy, and Rest of Europe

•           Asia-Pacific: Australia & New Zealand, Japan, India, ASEAN countries, South Korea, China, and Rest of Asia-Pacific

•           Latin America: Mexico, Brazil, and Rest of Latin America

•        Middle East and Africa: The United Arab Emirates, Turkey, Saudi Arabia, South Africa, and Rest of Middle East & Africa

The global Alzheimer’s disease therapeutics and diagnostics market has been segmented as follows:

•           By Therapeutics and Diagnostics

o          Therapeutics

•           Therapeutics by Drugs

o          Marketed Drugs

o          Pipeline Drugs

•           Therapeutics by Disease Stage

o          Late-Stage: Severe AD

o          Early/Middle Stage: Mild to Moderate AD

o          Prodromal Stage

•           Therapeutics by Generic and Branded

o          Branded

o          Generic

o          Diagnostics

•           Lumbar Puncture Test

•           Positron Emission Tomography

•           Electroencephalography

•           Magnetic Resonance Imaging

•           Computed Tomography

•           Blood Test

•           Other Diagnostics

The key players engaged in the Alzheimer’s disease therapeutics and diagnostics market are Novartis AG, GE Healthcare, Zydus Cadila, Lupin Limited, Merck & Co Inc, Siemens Healthineers AG, Baxter International Inc, Eisai Co Ltd, Eli Lilly & Company, Amarantus Bioscience Holdings Inc, Johnson & Johnson, F Hoffmann La Roche, Cognoptix Inc, Sun Pharmaceuticals Industries Ltd, Luye Pharma Group, Allergan Plc acquired by Abbvie, Teva Pharmaceutical Industries Limited, Biogen Inc, Pfizer Inc, and PeopleBio Co.

The strategic analysis for each of these companies has been covered in detail. The global Alzheimer’s disease therapeutics and diagnostics market by company profile helps dive into data about the key market players in this industry.

Related Reports

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027
Lifesciences

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027

Market By Type, Application, E ..

VIEW REPORT
ASIA PACIFIC BIOCHIPS MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOCHIPS MARKET 2019-2027

Market By Type, Substrate Mate ..

VIEW REPORT
ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027

Market By Device Type, Therape ..

VIEW REPORT
ASIA PACIFIC DNA VACCINES MARKET 2019-2027
Lifesciences

ASIA PACIFIC DNA VACCINES MARKET 2019-2027

Market By Type, Application, T ..

VIEW REPORT
ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027
Lifesciences

ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027

Market By Technology, Applicat ..

VIEW REPORT
ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028
Lifesciences

ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028

Market By Application, Type, E ..

VIEW REPORT

Table of Content

1. GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – SUMMARY

2. INDUSTRY OUTLOOK

2.1. KEY INSIGHTS

2.2. IMPACT OF COVID-19 ON THE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET

2.3. PORTER’S FIVE FORCES MODEL

2.3.1. THREAT OF NEW ENTRANTS

2.3.2. THREAT OF SUBSTITUTE PRODUCTS

2.3.3. BARGAINING POWER OF BUYERS

2.3.4. BARGAINING POWER OF SUPPLIERS

2.3.5. COMPETITIVE RIVALRY

2.4. KEY BUYING IMPACT ANALYSIS

2.5. INDUSTRY COMPONENTS

2.6. DIFFERENT PHASES OF ALZHEIMER’S DISEASE

2.7. MARKET ATTRACTIVENESS INDEX

2.8. VENDOR SCORECARD

2.9. KEY STRATEGIC DEVELOPMENTS

2.9.1. CONTRACTS & PARTNERSHIPS

2.9.2. DIVESTITURES BUSINESS EXPANSIONS & DIVESTITURES

2.9.3. ACQUISITIONS & MERGERS

2.9.4. NEW PRODUCT LAUNCHES

2.10. MARKET DRIVERS

2.10.1. GROWING DEMENTIA AMONG THE ELDERLY

2.10.2. HIGH PREVALENCE OF ALZHEIMER’S DISEASE IN DEVELOPED COUNTRIES

2.10.3. LAUNCH OF NEW DRUGS AND THE PREVAILING CLINICAL TRIALS RESULTING IN ROBUST MARKET GROWTH

2.11. MARKET CHALLENGES

2.11.1. STRINGENT REGULATIONS ASSOCIATED WITH DRUG DEVELOPMENT AND CLINICAL TRIALS

2.11.2. FAILURE OF THE LATE-STAGE DRUGS TO INDUCE SIGNIFICANT IMPROVEMENT IN SYMPTOMS

2.12. MARKET OPPORTUNITIES

2.12.1. EMERGING NOVEL DIAGNOSTIC TECHNOLOGIES FOR ALZHEIMER’S DISEASE TREATMENT

3. GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – BY THERAPEUTICS AND DIAGNOSTICS

3.1. THERAPEUTICS

3.1.1. THERAPEUTICS BY DRUGS

3.1.1.1. MARKETED DRUGS

3.1.1.2. PIPELINE DRUGS

3.1.2. THERAPEUTICS BY DISEASE STAGE

3.1.2.1. LATE STAGE: SEVERE AD

3.1.2.2. EARLY/MIDDLE STAGE: MILD TO MODERATE AD

3.1.2.3. PRODROMAL STAGE

3.1.3. THERAPEUTICS BY GENERIC AND BRANDED

3.1.3.1. BRANDED

3.1.3.2. GENERIC

3.2. DIAGNOSTICS

3.2.1. LUMBAR PUNCTURE TEST

3.2.2. POSITRON EMISSION TOMOGRAPHY

3.2.3. ELECTROENCEPHALOGRAPHY

3.2.4. MAGNETIC RESONANCE IMAGING

3.2.5. COMPUTED TOMOGRAPHY

3.2.6. BLOOD TEST

3.2.7. OTHER DIAGNOSTICS

4. GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – REGIONAL OUTLOOK

4.1. NORTH AMERICA

4.1.1. MARKET BY THERAPEUTICS AND DIAGNOSTICS

4.1.1.1. THERAPEUTICS MARKET BY DRUGS

4.1.1.2. THERAPEUTICS MARKET BY DISEASE STAGE

4.1.1.3. THERAPEUTICS MARKET BY GENERIC AND BRANDED

4.1.1.4. DIAGNOSTICS MARKET BY TYPE

4.1.2. COUNTRY ANALYSIS

4.1.2.1. THE UNITED STATES

4.1.2.2. CANADA

4.2. EUROPE

4.2.1. MARKET BY THERAPEUTICS AND DIAGNOSTICS

4.2.1.1. THERAPEUTICS MARKET BY DRUGS

4.2.1.2. THERAPEUTICS MARKET BY DISEASE STAGE

4.2.1.3. THERAPEUTICS MARKET BY GENERIC AND BRANDED

4.2.1.4. DIAGNOSTICS MARKET BY TYPE

4.2.2. COUNTRY ANALYSIS

4.2.2.1. UNITED KINGDOM

4.2.2.2. FRANCE

4.2.2.3. GERMANY

4.2.2.4. ITALY

4.2.2.5. RUSSIA

4.2.2.6. SPAIN

4.2.2.7. REST OF EUROPE

4.3. ASIA-PACIFIC

4.3.1. MARKET BY THERAPEUTICS AND DIAGNOSTICS

4.3.1.1. THERAPEUTICS MARKET BY DRUGS

4.3.1.2. THERAPEUTICS MARKET BY DISEASE STAGE

4.3.1.3. THERAPEUTICS MARKET BY GENERIC AND BRANDED

4.3.1.4. DIAGNOSTICS MARKET BY TYPE

4.3.2. COUNTRY ANALYSIS

4.3.2.1. CHINA

4.3.2.2. INDIA

4.3.2.3. JAPAN

4.3.2.4. AUSTRALIA & NEW ZEALAND

4.3.2.5. SOUTH KOREA

4.3.2.6. ASEAN COUNTRIES

4.3.2.7. REST OF ASIA-PACIFIC

4.4. LATIN AMERICA

4.4.1. MARKET BY THERAPEUTICS AND DIAGNOSTICS

4.4.1.1. THERAPEUTICS MARKET BY DRUGS

4.4.1.2. THERAPEUTICS MARKET BY DISEASE STAGE

4.4.1.3. THERAPEUTICS MARKET BY GENERIC AND BRANDED

4.4.1.4. DIAGNOSTICS MARKET BY TYPE

4.4.2. COUNTRY ANALYSIS

4.4.2.1. BRAZIL

4.4.2.2. MEXICO

4.4.2.3. REST OF LATIN AMERICA

4.5. MIDDLE EAST AND AFRICA

4.5.1. MARKET BY THERAPEUTICS AND DIAGNOSTICS

4.5.1.1. THERAPEUTICS MARKET BY DRUGS

4.5.1.2. THERAPEUTICS MARKET BY DISEASE STAGE

4.5.1.3. THERAPEUTICS MARKET BY GENERIC AND BRANDED

4.5.1.4. DIAGNOSTICS MARKET BY TYPE

4.5.2. COUNTRY ANALYSIS

4.5.2.1. SAUDI ARABIA

4.5.2.2. UNITED ARAB EMIRATES

4.5.2.3. TURKEY

4.5.2.4. SOUTH AFRICA

4.5.2.5. REST OF MIDDLE EAST & AFRICA

5. COMPANY PROFILES

5.1. ALLERGAN PLC ACQUIRED BY ABBVIE

5.2. AMARANTUS BIOSCIENCE HOLDINGS INC

5.3. BAXTER INTERNATIONAL INC

5.4. BIOGEN INC

5.5. COGNOPTIX INC

5.6. EISAI CO LTD

5.7. ELI LILLY & COMPANY

5.8. F HOFFMANN LA ROCHE

5.9. GE HEALTHCARE

5.10. JOHNSON & JOHNSON

5.11. LUPIN LIMITED

5.12. LUYE PHARMA GROUP

5.13. MERCK & CO INC

5.14. NOVARTIS AG

5.15. PEOPLEBIO CO

5.16. PFIZER INC

5.17. SIEMENS HEALTHINEERS AG

5.18. SUN PHARMACEUTICALS INDUSTRIES LTD

5.19. TEVA PHARMACEUTICAL INDUSTRIES LIMITED

5.20. ZYDUS CADILA

6. RESEARCH METHODOLOGY & SCOPE

6.1. RESEARCH SCOPE & DELIVERABLES

6.1.1. OBJECTIVES OF STUDY

6.1.2. SCOPE OF STUDY

6.2. SOURCES OF DATA

6.2.1. PRIMARY DATA SOURCES

6.2.2. SECONDARY DATA SOURCES

6.3. RESEARCH METHODOLOGY

6.3.1. EVALUATION OF PROPOSED MARKET

6.3.2. IDENTIFICATION OF DATA SOURCES

6.3.3. ASSESSMENT OF MARKET DETERMINANTS

6.3.4. DATA COLLECTION

6.3.5. DATA VALIDATION & ANALYSIS

List of Tables

TABLE 1: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2021-2028 (IN $ MILLION)

TABLE 2: VENDOR SCORECARD

TABLE 3: LIST OF CONTRACTS & PARTNERSHIPS

TABLE 4: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

TABLE 5: LIST OF ACQUISITIONS & MERGERS

TABLE 6: LIST OF NEW PRODUCT LAUNCHES

TABLE 7: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND DIAGNOSTICS, 2021-2028 (IN $ MILLION)

TABLE 8: GLOBAL THERAPEUTICS MARKET, BY DRUGS, 2021-2028 (IN $ MILLION)

TABLE 9: GLOBAL THERAPEUTICS MARKET, BY DISEASE STAGE, 2021-2028 (IN $ MILLION)

TABLE 10: GLOBAL THERAPEUTICS MARKET, BY GENERIC AND BRANDED, 2021-2028 (IN $ MILLION)

TABLE 11: GLOBAL DIAGNOSTICS MARKET, BY TYPE, 2021-2028 (IN $ MILLION)

TABLE 12: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2021-2028 (IN $ MILLION)

TABLE 13: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021-2028 (IN $ MILLION)

TABLE 14: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND DIAGNOSTICS, 2021-2028 (IN $ MILLION)

TABLE 15: NORTH AMERICA THERAPEUTICS MARKET, BY DRUGS, 2021-2028 (IN $ MILLION)

TABLE 16: NORTH AMERICA THERAPEUTICS MARKET, BY DISEASE STAGE, 2021-2028 (IN $ MILLION)

TABLE 17: NORTH AMERICA THERAPEUTICS MARKET, BY GENERIC AND BRANDED, 2021-2028 (IN $ MILLION)

TABLE 18: NORTH AMERICA DIAGNOSTICS MARKET, BY TYPE, 2021-2028 (IN $ MILLION)

TABLE 19: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021-2028 (IN $ MILLION)

TABLE 20: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND DIAGNOSTICS, 2021-2028 (IN $ MILLION)

TABLE 21: EUROPE THERAPEUTICS MARKET, BY DRUGS, 2021-2028 (IN $ MILLION)

TABLE 22: EUROPE THERAPEUTICS MARKET, BY DISEASE STAGE, 2021-2028 (IN $ MILLION)

TABLE 23: EUROPE THERAPEUTICS MARKET, BY GENERIC AND BRANDED, 2021-2028 (IN $ MILLION)

TABLE 24: EUROPE DIAGNOSTICS MARKET, BY TYPE, 2021-2028 (IN $ MILLION)

TABLE 25: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021-2028 (IN $ MILLION)

TABLE 26: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND DIAGNOSTICS, 2021-2028 (IN $ MILLION)

TABLE 27: ASIA-PACIFIC THERAPEUTICS MARKET, BY DRUGS, 2021-2028 (IN $ MILLION)

TABLE 28: ASIA-PACIFIC THERAPEUTICS MARKET, BY DISEASE STAGE, 2021-2028 (IN $ MILLION)

TABLE 29: ASIA-PACIFIC THERAPEUTICS MARKET, BY GENERIC AND BRANDED, 2021-2028 (IN $ MILLION)

TABLE 30: ASIA-PACIFIC DIAGNOSTICS MARKET, BY TYPE, 2021-2028 (IN $ MILLION)

TABLE 31: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021-2028 (IN $ MILLION)

TABLE 32: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND DIAGNOSTICS, 2021-2028 (IN $ MILLION)

TABLE 33: LATIN AMERICA THERAPEUTICS MARKET, BY DRUGS, 2021-2028 (IN $ MILLION)

TABLE 34: LATIN AMERICA THERAPEUTICS MARKET, BY DISEASE STAGE, 2021-2028 (IN $ MILLION)

TABLE 35: LATIN AMERICA THERAPEUTICS MARKET, BY GENERIC AND BRANDED, 2021-2028 (IN $ MILLION)

TABLE 36: LATIN AMERICA DIAGNOSTICS MARKET, BY TYPE, 2021-2028 (IN $ MILLION)

TABLE 37: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021-2028 (IN $ MILLION)

TABLE 38: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND DIAGNOSTICS, 2021-2028 (IN $ MILLION)

TABLE 39: MIDDLE EAST AND AFRICA THERAPEUTICS MARKET, BY DRUGS, 2021-2028 (IN $ MILLION)

TABLE 40: MIDDLE EAST AND AFRICA THERAPEUTICS MARKET, BY DISEASE STAGE, 2021-2028 (IN $ MILLION)

TABLE 41: MIDDLE EAST AND AFRICA THERAPEUTICS MARKET, BY GENERIC AND BRANDED, 2021-2028 (IN $ MILLION)

TABLE 42: MIDDLE EAST AND AFRICA DIAGNOSTICS MARKET, BY TYPE, 2021-2028 (IN $ MILLION)

List of Figures

FIGURE 1: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2021-2028 (IN $ MILLION)

FIGURE 2: INDUSTRY COMPONENTS

FIGURE 3: PIPELINE DRUGS RELATED TO ALZHEIMER’S DISEASE

FIGURE 4: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2021-2028 (IN $ MILLION)

FIGURE 5: GLOBAL THERAPEUTICS MARKET, BY MARKETED DRUGS, 2021-2028 (IN $ MILLION)

FIGURE 6: GLOBAL THERAPEUTICS MARKET, BY PIPELINE DRUGS, 2021-2028 (IN $ MILLION)

FIGURE 7: GLOBAL THERAPEUTICS MARKET, BY LATE STAGE: SEVERE AD, 2021-2028 (IN $ MILLION)

FIGURE 8: GLOBAL THERAPEUTICS MARKET, BY EARLY/MIDDLE STAGE: MILD TO MODERATE AD, 2021-2028 (IN $ MILLION)

FIGURE 9: GLOBAL THERAPEUTICS MARKET, BY PRODROMAL STAGE, 2021-2028 (IN $ MILLION)

FIGURE 10: GLOBAL THERAPEUTICS MARKET, BY BRANDED, 2021-2028 (IN $ MILLION)

FIGURE 11: GLOBAL THERAPEUTICS MARKET, BY GENERIC, 2021-2028 (IN $ MILLION)

FIGURE 12: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2021-2028 (IN $ MILLION)

FIGURE 13: GLOBAL DIAGNOSTICS MARKET, BY LUMBAR PUNCTURE TEST, 2021-2028 (IN $ MILLION)

FIGURE 14: GLOBAL DIAGNOSTICS MARKET, BY POSITRON EMISSION TOMOGRAPHY, 2021-2028 (IN $ MILLION)

FIGURE 15: GLOBAL DIAGNOSTICS MARKET, BY ELECTROENCEPHALOGRAPHY, 2021-2028 (IN $ MILLION)

FIGURE 16: GLOBAL DIAGNOSTICS MARKET, BY MAGNETIC RESONANCE IMAGING, 2021-2028 (IN $ MILLION)

FIGURE 17: GLOBAL DIAGNOSTICS MARKET, BY COMPUTED TOMOGRAPHY, 2021-2028 (IN $ MILLION)

FIGURE 18: GLOBAL DIAGNOSTICS MARKET, BY BLOOD TEST, 2021-2028 (IN $ MILLION)

FIGURE 19: GLOBAL DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2021-2028 (IN $ MILLION)

FIGURE 20: THE UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS 2021-2028 (IN $ MILLION)

FIGURE 21: CANADA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS 2021-2028 (IN $ MILLION)

FIGURE 22: UNITED KINGDOM ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2021-2028 (IN $ MILLION)

FIGURE 23: FRANCE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2021-2028 (IN $ MILLION)

FIGURE 24: GERMANY ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2021-2028 (IN $ MILLION)

FIGURE 25: ITALY ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2021-2028 (IN $ MILLION)

FIGURE 26: RUSSIA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2021-2028 (IN $ MILLION)

FIGURE 27: SPAIN ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2021-2028 (IN $ MILLION)

FIGURE 28: REST OF EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2021-2028 (IN $ MILLION)

FIGURE 29: CHINA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2021-2028 (IN $ MILLION)

FIGURE 30: INDIA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2021-2028 (IN $ MILLION)

FIGURE 31: JAPAN ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2021-2028 (IN $ MILLION)

FIGURE 32: AUSTRALIA & NEW ZEALAND ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2021-2028 (IN $ MILLION)

FIGURE 33: SOUTH KOREA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2021-2028 (IN $ MILLION)

FIGURE 34: ASEAN COUNTRIES ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2021-2028 (IN $ MILLION)

FIGURE 35: REST OF ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2021-2028 (IN $ MILLION)

FIGURE 36: BRAZIL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET 2021-2028 (IN $ MILLION)

FIGURE 37: MEXICO ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET 2021-2028 (IN $ MILLION)

FIGURE 38: REST OF LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET 2021-2028 (IN $ MILLION)

FIGURE 39: SAUDI ARABIA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET 2021-2028 (IN $ MILLION)

FIGURE 40: UNITED ARAB EMIRATES ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET 2021-2028 (IN $ MILLION)

FIGURE 41: TURKEY ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET 2021-2028 (IN $ MILLION)

FIGURE 42: SOUTH AFRICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET 2021-2028 (IN $ MILLION)

FIGURE 43: REST OF MIDDLE EAST & AFRICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET 2021-2028 (IN $ MILLION)

Purchase Options

  • Licence Type
  • Price
  • User/Sharing
  • Printing
  • Delivery Formats
  • Free customization (Pre-sale)
  • Analyst hour support (Post Sale)
  • Customized notification for newly published report
  • Free report on update (within 180 days)

Single User PDF

$2,750.00

  • User/Sharing
  • Restricted to one authorized user
  • Printing
  • Not printable
  • Delivery Formats
  • Pdf
  • Free customization (Pre-sale)
  • 10% Free customization
  • Analyst hour support (Post Sale)
  • 3 hours
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Enterprise Online/PDF

$4,000.00

  • User/Sharing
  • Unlimited
  • Printing
  • Unlimited
  • Delivery Formats
  • Pdf and market estimation excel
  • Free customization (Pre-sale)
  • 20% Free customization
  • Analyst hour support (Post Sale)
  • 8 hour
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Request free Sample

SUBMIT REQUEST
Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

;